Nicholas Lukacs to Speak at Cytokines Conference Jan 31, 2013 in San Diego, CA

MONROVIA, CA, December 14, 2012

Nicholas W. Lukacs, Professor of Pathology and Assistant Dean for Faculty Affairs at the University of Michigan will give a presentation on "Targeting SCF in Chronic Pulmonary Disease" at the 11th Cytokines and Inflammation Conference to be held in San Diego, CA on January 31 - February 1, 2013 by GTC.

A member of the U-M faculty for more than 15 years, Dr. Lukacs researches the development of chronic pulmonary diseases, including asthma and viral infections. His laboratory developed clinically relevant mouse models of allergen-induced asthma and viral infection that have demonstrated a number of correlates to human disease. His research into the role of specific innate and acquired immune responses has identified several novel pathways of disease intervention as well as defined mechanisms leading to pathophysiology changes during pulmonary disease.

Dr. Lukacs is principal investigator on four National Institute of Health grants, co-investigator on four colleagues' NIH grants, and has received industry support from a wide range of pharmaceutical and biotech companies. In addition, he has two patents and four disclosures, has authored 209 peer-reviewed articles, 48 review articles and book chapters, and has delivered more than 100 extramural invited presentations.

The GTC Cytokines and Inflammation conferences have become an established meeting point for academic scientists and industry clinical developers to exchange their complementary approaches in the field of cytokine biology. The organizations participating are a great selection of innovative medical organizations from academia (City of Hope, NCI, NIH, USC, Sanford-Burnham, Cleveland Clinic, UCLA, University of Florida, etc.), industry (Amgen, Bristol-Myers Squibb, Genentech, HUMIGEN, MedImmune, Biogen Idec, Merck Serono, Novo Nordisk, etc.) and, last but not -by any means- least, the US FDA.

This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of a workshop, this track and three other concurrent tracks:
1) 5th Immunotherapeutics & Immunomonitoring
2) 2nd Allergy & Respiratory Drug Discovery
3) Immunotoxicity & Immunogenicity
4) Workshop: Immune Responses in Tumor Microenvironment

For more information, please visit http://www.gtcbio.com

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.